Prognostic Significance of TOP2A Gene Dosage in HER-2-Negative Breast Cancer

Oncologist

Volumn 17, Issue 10, 2012, Pages 1246-1255

  Zaczek, Anna J ^a   Markiewicz, Aleksandra ^a,b   Seroczyńska, Barbara ^c   Skokowski, Jarosław ^a,c   Jáskiewicz, Janusz ^a   Piénkowski, Tadeusz ^d   Olszewski, Wojciech P ^d   Szade, Jolanta ^a   Rhone, Piotr ^e   Wełnicka Jáskiewicz, Marzena ^a   Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Bank of Frozen Tissues and Genetic Specimen ^*  (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e Cancer Center   (Poland)

Author keywords

Breast cancer; Prognostic factor; Quantitative real time PCR; TOP2A gene dosage

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 84868097825     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0023     Document Type: Article

References (38)

1. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing. Nucleic Acids Res 2009;37:738-748.
2. Ross JS, Fletcher JA, Linette GP et al. The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. The Oncologist 2003;8:307-325.
3. Zaczek A, Welnicka-Jaskiewicz M, Bielawski KP et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol 2008;134:271-279.
4. Hicks DG, Yoder BJ, Pettay J et al. The incidence of topoisomerase II-α genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study. Hum Pathol 2005;36:348-356.
5. Järvinen TA, Tanner M, BärlundMet al. Characterization of topoisomerase II α gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150.
6. Nielsen KV, Ml̈ler S, Mller S et al. Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 2010;4:161-168.
7. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracyclinebased therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116.
8. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-α gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011;29:859-867.
9. Di Leo A, Desmedt C, Bartlett JM et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: A meta-analysis of individual patient data. Lancet Oncol 2011;12:1134-1142.
10. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-7490.
11. O'Malley FP, Chia S, Tu D et al. Topoisomerase II α and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644-650.
12. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracyclinebased adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24:2428-2436.
13. Zaczek A, Markiewicz A, Jaskiewicz J et al. Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem 2010;43:891-898.
14. Järvinen T, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
15. Olsen KE, Knudsen H, Rasmussen BB et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35-42.
16. Brase JC, Schmidt M, Fischbach T et al. ERBB2 and TOP2A in breast cancer: A comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010;16:2391-2401.
17. Durham TA, Turner JR. Probability, Hypothesis Testing, and Estimation, Introduction to Statistics in Pharmaceutical Clinical Trials. London: Pharmaceutical Press, 2008:1-240.
18. Zaczek A, Markiewicz A, Supernat A et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res 2012 Mar 18 [Epub ahead of print].
19. Di Leo A, Larsimont D, Gancberg D et al. Her-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001;12:1081-1089.
20. Arriola E, Rodriguez-Pinilla SM, Lambros MB et al. Topoisomerase II α amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007;106:181-189.
21. Romero A, Martín M, Cheang MC et al. Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 2011;178:1453-1460.
22. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123:889-895.
23. Konecny GE, Pauletti G, Untch M et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 2010; 120:481-489.
24. Park K, Han S, GwakGHet al. Topoisomerase II-α gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 2006;98:337-342.
25. Patent Application Publication, International Application No PCT/US2006/047732. Wigler MH, Hicks JB, Norton L, et al. Use of ROMA for characterizing genomic rearrangements. Patent Application Publication, 2007. Available at http://patentscope.wipo.int/search/en/detail.jsf?docId_WO2007070640&recNum_ 1&maxRec_&office_&prevFilter_&sortOption_ &queryString_&tab_PCT_Biblio, accessed August 2, 2012.
26. Glynn RW, Mahon S, Curran C et al. TOP2A amplification in the absence of that of HER-2/neu: Toward individualization of chemotherapeutic practice in breast cancer. The Oncologist 2011;16:949-955.
27. Rody A, Karn T, Ruckhäberle E et al. Gene expression of topoisomerase II α (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009; 113:457-466.
28. Sparano JA, Goldstein LJ, Childs BH et al. Relationship between topoisomerase 2a RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009;15:7693-7700.
29. Harris LN, Broadwater G, Abu-KhalafMet al. Topoisomerase IIα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: Results of CALGB 8541/150013. J Clin Oncol 2009;27:3430-3436.
30. Slamon DJ, Press MF. Alterations in the TOP2 and HER2 genes: Association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 2009;101:615-618.
31. Kreipe H, Alm P, Olsson H et al. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 1993;142: 651-657.
32. Bildrici K, Tel N, Ozalp SS et al. Prognostic significance of DNA topoisomerase II-α (Ki-S1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol 2002;23:540-544.
33. Fountzilas G, Valavanis C, Kotoula V et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 2012;10:10.
34. Mueller RE, Parkes RK, Andruli I et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II α protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39:288-297.
35. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: Analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010;120:1-7.
36. Lamy PJ, Fina F, Bascoul-Mollevi C et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res 2011;13:R15.
37. Lehmann U, Glöckner S, Kleeberger W et al. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000;156:1855-1864.
38. Nielsen KV, Ejlertsen B, Mller S et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-734.